Recent advances and future directions in amphiphilic cyclodextrin nanoparticles

Expert Opinion on Drug Delivery

Volumn 6, Issue 11, 2009, Pages 1161-1173

  Bilensoy, Erem ^a   Hincal, A Atilla ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

amphiphilic cyclodextrin; encapsulation; nanoparticle; preparation; synthesis

Indexed keywords

ALPHA CYCLODEXTRIN; AMPHIPHILIC CYCLODEXTRIN NANOPARTICLE; ANIONIC AMPHIPHILIC CYCLODEXTRIN; BETA CYCLODEXTRIN; CAMPTOTHECIN; CATIONIC AMPHIPHILIC CYCLODEXTRIN; CYCLODEXTRIN; CYCLODEXTRIN DERIVATIVE; DOCETAXEL; FLUOROPHILIC CYCLODEXTRIN; GAMMA CYCLODEXTRIN; HEPTAKIS(2 OMEGA AMINO O OLIGO(ETHYLENE OXIDE)HEXYLTHIO BETA CYCLODEXTRIN; INDOMETACIN; NANOCAPSULE; NANOPARTICLE; NANOSPHERE; NON IONIC AMPHIPHILIC CYCLODEXTRIN; PACLITAXEL; TAMOXIFEN; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG; DRUG CARRIER; SURFACTANT;

ANTINEOPLASTIC ACTIVITY; ATOMIC FORCE MICROSCOPY; AUTOCLAVE; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL DAMAGE; CELL DEATH; CONTROLLED RELEASE FORMULATION; CONVENTIONAL LOADING; CYTOTOXICITY; DETERGENT REMOVAL TECHNIQUE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PACKAGING; DRUG RELEASE; DRUG SOLUBILITY; DRUG SOLUTION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; EMULSION SOLVENT EVAPORATION TECHNIQUE; ENCAPSULATION; FILTRATION; FREEZE FRACTURE; GAMMA IRRADIATION; GENE EXPRESSION; GENERAL AND MISCELLANEOUS PROCEDURES AND TECHNIQUES; GENETIC TRANSCRIPTION; HIGH LOADING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; LIPOPHILICITY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NANOPRECIPITATION TECHNIQUE; NONHUMAN; PARTICLE SIZE; PHOTODYNAMICS; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PRE LOADING; PRECIPITATION; REVIEW; SCANNING ELECTRON MICROSCOPE; SCANNING TUNNELING MICROSCOPY; SULFATION; SURFACE CHARGE; SUSTAINED DRUG RELEASE; THIN LAYER CHROMATOGRAPHY; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CHEMISTRY; METHODOLOGY; SYNTHESIS; ULTRASTRUCTURE;

ANIMALS; CYCLODEXTRINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; SURFACE-ACTIVE AGENTS;

EID: 75349099438     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425240903222218     Document Type: Review

References (97)

1. Albers E, M'ller BW. Cyclodextrin derivatives in pharmaceuticals. CRC Crit Rev Ther Drug Carrier Syst 1995;12(4):311-37
2. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007;329(1-2):1-11
3. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull 2004;52(8):900-15
4. Wenz G. Synthesis and characterization of some lipophilic per (2,6-di-O-alkyl) cyclomaltooligosaccharides. Carbohydr Res 1991;214:257-65
5. Duchene D, Wouessidjewe D. Industrial uses of cyclodextrins and their derivatives. J Coord Chem 1992;27:223-36
6. Thompson DO. Cyclodextrins as enabling excipients: their present and future use in pharmaceuticals. CRC Crit Rev Ther Drug Carrier Syst 1997;14(1):1-110
7. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins 2. In vivo drug delivery. J Pharm Sci 1996;85(11):1142-69
8. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins I. Drug solubilization and stabilization. J Pharm Sci 1996;85(10):1017-25
9. Frank DW, Gray JE, Weaver RN. Cyclodextrin nephrosis in the rat. Am J Pathol 1976;83:367-82
10. Szejtli J, Cserhati T, Sz'gyi M. Interactions between cyclodextrins and cell-membrane phospholipids. Carbohydr Polym 1986;6:35-49
11. Debouzy JC, Fauvelle F, Crouzy S, et al. Mechanism of ?-cyclodextrin induced hemolysis 2. A study of the factors controlling the association with serine-, ethanolamine- and choline-phospholipids. J Pharm Sci 1997;87(1):59-66
12. Memis?oǧlu E, Bochot A, S?en M, et al. Non-surfactant nanospheres of progesterone inclusion complexes with amphiphilic β-cyclodextrins. Int J Pharm 2003;251:143-53
13. Monza de Silveira A, Ponchel G, Puisieux F, Duchene D. Combined poly(isobutylcyanoacrylate) and cyclodextrin nanoparticles for enhancing the encapsulation of lipophilic drug. Pharm Res 1998;15(7):1051-5
14. Duchene D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting. Application to nanoparticles. Adv Drug Deliv Rev 1999;36:29-40
15. Munoz M, Deschenaux R, Coleman AW. Observation of microscopic patterning at the air/water interface by mixtures of amphiphilic cyclodextrins-a comparison isotherm and Brewster angle microscopy study. J Phys Org Chem 1999;12:364-9
16. Duchene D, Wouessidjewe D, Ponchel G. Cyclodextrins and carrier systems. J Control Rel 1999;62:263-8
17. Memisoglu-Bilensoy E, Bochot A, Trichard L, et al. Amphiphilic cyclodextrins and microencapsulation. In: Benita S, editor, Microencapsulation- second and revised edition. New York: Taylor & Francis Ltd; 2005. p. 269-95
18. Bilensoy E, Dǒgan AL, Şen M, Hincal AA. Complexation behaviour of antiestrogen drug tamoxifen citrate with natural and modified cyclodextrins. J Inclus Phenom Macroc Chem 2007;57:651-4
19. Bellanger N, Perly B. NMR investigations of the conformation of new cyclodextrins-based amphiphilic transporters for hydrophobic drugs: molecular lollipops. J Mol Struct 1992;15:215-26
20. Dodziuk H, Chmurski K, Jurczak J, et al. A dynamic NMR study of self-inclusion of a pendant group in amphiphilic 6-thiophenyl-6- deoxycyclodextrins. J Mol Struct 2000;519:33-6
21. Lin J. Synthése des cyclodextrins amphiphiles et étude de leur incorporation dans des phases phospholipidiques, PhD dissertation, University of Paris VI, Paris; 1995
22. Kawabata Y, Matsumoto M, Tanaka M, et al. Formation and deposition of monolayers of amphiphilic β-cyclodextrin derivatives. Chem Lett 1983;1933-4
23. Djedaini F, Coleman AW, Perly B. New cyclodextrins based media for vectorization of hydrophilic drug, mixed vesicles composed of phospholipids and lipophilic cyclodextrins. In: Duchene D, editor, Minutes of the 5th International Symposium on Cyclodextrins. Paris, Editions de Santé; 1990. p. 328-31
24. Liu FY, Kildsig DO, Mitra AK. Complexation of 6-acyl-O-β- cyclodextrin derivatives with steroids, effects of chain length and substitution degree. Drug Del Ind Pharm 1992;18:1599-612
25. Zhang P, Ling CC, Coleman AW, et al. Formation of amphiphilic cyclodextrins via hydrophobic esterification at the secondary hydroxyl face. Tetrahedron Lett 1991;32:2769-70
26. Zhang P, Parrot-Lopez H. Self-organizing systems based on amphiphilic cyclodextrins diesters. J Phys Org Chem 1992:518-28
27. Memis?oǧlu E, Charon D, Duchene D, HIncal AA. Synthesis of per(2,3-di-O-hexanoyl)-β-cyclodextrin and characterization amphiphilic cyclodextrins nanoparticles. In: Torres-Labandeira J, Vila-Jato J, editors, Proceedings of the 9th International Symposium on Cyclodextrins, Kluwer Academic Publishers: Dordrecht; 1999. p. 622-4
28. Lesieur S, Charon D, Lesieur P, et al. Phase behaviour of fully-hydrated DMPC-amphiphilic cyclodextrin systems. Chem Phys Lipids 2000;10:127-44
29. Canceill J, Jullien L, Lacombe L, Lehn JM. Channel type molecular structures, Part 2, synthesis of bouquet-shaped molecules based on a β-cyclodextrin core. Helv Chim Acta 1992;75:791-812
30. Auzely-Velty R, Djedaini-Pilard F, Desert S, et al. Micellization of hydrophobically modified cyclodextrins 1. Miceller structures. Langmuir 2000;16:3727-34
31. Tchoreloff P, Boissonnade MM, Coleman AW, Baszkin A. Amphiphilic monolayers of insoluble cyclodextrins at the water/air interface. Surface pressure and surface potential studies. Langmuir 1995;11:191-6
32. Ringard-Lefebvre C, Bochot A, Memis?oǧ lu E, et al. Effect of spread amphiphilic β-cyclodextrins on interfacial properties of the oil/water system. Colloids Surf B Biointerfaces 2002;25:109-17
33. Memis?oǧlu E, Bochot A, S?en M, et al. Amphiphilic β-cyclodextrins modified on the primary face: synthesis, characterization and evaluation of their potential as novel excipients in the preparation of nanocapsules. J Pharm Sci 2002;95(1):1214-24
34. Alexandre S, Coleman AW, Kasselouri A, Valleton JM. Scanning force microscopy investigation of amphiphilic cyclodextrin Langmuir-Blodgett films. Thin Solid Films 1996;284-285:765-8
35. Tanaka M, Ishizuka U, Matsumoto M, et al. Host-guest complexes of an amphiphilic β-cyclodextrin and azobenzene derivatives in Langmuir-Blodgett films. Chem Lett 1987;1307-10
36. Mazzaglia A, Angelini N, Darcy R, et al. Novel heterotropic colloids of anionic porphyrins entangled in cationic amphiphilic cyclodextrins: spectroscopic investigation and intracellular delivery. Chem Eur J 2003;9:5762-9
37. Matsumoto M, Matsuzawa Y, Noguchi S, et al. Structure of Langmuir-Blodgett films of amphiphilic cyclodextrin and water-soluble benzophenone. Mol Cryst Liq Cryst 2004;425:197-204
38. Cryan SA, Holohan A, Donohue R, et al. Cell transfection with polycationic cyclodextrin vectors. Eur J Pharm Sci 2004;21:625-33
39. Dubes A, Bouchu D, Lamartine R, Parrot-Lopez H. An efficient regiospecific synthetic route to multiply substituted acyl-sulphated β-cyclodextrins. Tetrahedron Lett 2001;42:9147-51
40. Dubes A, Degobert G, Fessi H, Parrot-Lopez H. Synthesis and characterisation of sulfated amphiphilic alpha-, beta- and gamma-cyclodextrins: application to the complexation of acyclovir. Carbohydr Res 2003;338:2185-93
41. Granger CE, Feliz CP, Parrot-Lopez H, Langlois BR. Fluroine containing β-cyclodextrin: a new class of amphiphilic carriers. Tetrahedron Lett 2000;41:9257-60
42. Peroche S, Degobert G, Putaux JL, et al. Synthesis and characterization of novel nanospheres made from amphiphilic perfluoroalkylthio-β- cyclodextrins. Eur J Pharm Biopharm 2005:60:123-31
43. Skiba M, Skiba-Lahiani M, Arnaud P. Design of nanocapsules based on novel fluorophilic cyclodextrin derivatives and their potential role in oxygen delivery. J Inclus Phenom Macroc Chem 2002;44:151-4
44. Fessi HC, Devissaguet JP, Puisieux F, Thies C. Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles. US Patent 5118528; 1997
45. Wouessidjewe D, Skiba M, Leroy-Lechat F, et al. A new concept in drug delivery based on 'skirt-shaped cyclodextrins aggregates' present state and future prospects. STP Pharma Sci 1996:6:21-6
46. Lemos-Senna E, Wouessidjewe D, Lesieur S, et al. Evaluation of the hydrophobic drug loading characteristics in nanoprecipitated amphiphilic cyclodextrins nanospheres. Pharm Dev Technol 1998;3:1-10
47. Skiba M, Wouessidjewe D, Fessi H, et al. Preparation et utilizations des nouveau systemes colloidaux dispersibles a base de cyclodextrines sous forme de nanocapsules. French Patent, 9207285; 1992
48. Lemos-Senna E, Wouessidjewe D, Lesieur S, Duchene D. Preparation of amphiphilic cyclodextrin nanospheres using the emulsion solvent evaporation method, influence of the surfactant on preparation and hydrophobic drug loading. Int J Pharm 1998;170:119-28
49. Lemos-Senna E. Contribution a l'etude pharmacotechnique et physico-chimique de nanospheres de cyclodextrins amphiphiles comme transporteurs de principes actifs, PhD thesis, Universite Paris-Sud; 1998
50. Memisoglu-Bilensoy E, Doǧan AL, Hincal AA. Cytotoxic evaluation of injectable amphiphilic cyclodextrin nanoparticles on fibroblasts and polymorphonuclear cells: surfactant effect. J Pharm Pharmacol 2006;58(5):585-9
51. Skiba M, Wouesidjewe D, Duchene D, Puisieux F. Development of new submicronic particles from chemical cyclodextrins Part I. Nanopsheres and influence of physico-chemical and technological factors on particle size. Int J Pharm 1996:129:113-21
52. Skiba M, Nemati F, Puisieux F, et al. Spontaneous formation of drug-containing amphiphilic cyclodextrin nanocapsules. Int J Pharm 1996;145:241-5
53. Bilensoy E, G?rkaynak O, Doǧan AL, Hincal AA. Safety and efficacy of amphiphilic β-cyclodextrin nanopsrticles for paclitaxel delivery. Int J Pharm 2008;347:163-70
54. Memis?oǧlu E, Bochot A, ?zalp M, et al. Direct formation of nanospheres from amphiphilic β-cyclodextrin inclusion complexes. Pharm Res 2002;20(1):117-25
55. Memişoǧlu-Bilensoy E, Şen M, Hincal AA. Effect of drug physicochemical properties on in vitro characteristics of amphiphilic cyclodextrin nanospheres and nanocapsules. J Microencapsul 2006;23(1):59-68
56. Lahiani-Skiba M, Bounoure F, Shawky-Tous S, et al. Optimization of entrapment of metronidazole in amphiphilic beta-cyclodextrin nanospheres. J Biomed Anal 2006;41(3):1017-21
57. Memis?oǧlu-Bilensoy E, Vural i, Renoir JM, et al. Tamoxifen citrate loaded amphiphilic β-cyclodextrin nanoparticles: in vitro characteriziation and cytotoxicity. J Control Rel 2005;104:489-96
58. Vural i, Memis?oǧlu-Bilensoy E, Renoir JM, et al. Transcription efficiency of tamoxifen citrate loaded β-cyclodextrin nanoparticles. J Drug Deliv Sci Technol 2005:15(5):339-42
59. Bilensoy E, G'rkaynak O, Ertan M, et al. Development of non-surfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J Pharm Sci 2008;97(4):1519-29
60. 'irpanli Y, Bilensoy E, Doǧan AL, 'alIş S. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. Eur J Pharm Biopharm 2009:doi:10.1016/j.ejpb.2009.04.013
61. 'irpanli Y, Bilensoy E, Passirani C, et al. Evaluation of camptothecin loaded nanoparticles for malignant gliomas, Leuven: Globalization of Pharmaceutics Education Network GPEN-2008: 2008
62. Geze A, Tieuchau L, Choisnard L, et al. Biodistribution of intravenously administered amphiphilic β-cyclodextrin nanospheres. Int J Pharm 2007;344:135-42
63. Quaglia F, Ostacolo L, Mazzaglia A, et al. The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials 2009;30:374-82
64. Sortino S, Mazzaglia A, Scolaro LM, et al. Nanoparticles of cationic amphiphilic cyclodextrins entangling anionic porphyrins as carrier-sensitizer system in photodynamic cancer therapy. Biomaterials 2006;27:4256-65
65. Abdelwahed W, Degobert G, Dubes A, et al. Sulfated and non-sulfated amphiphilic cyclodextrins: impact of their structural properties on the physicochemical properties of nanoparticles. Int J Pharm 2008;351:289-95
66. Ghera BB, Perret F, Chevalier Y, et al. Novel nanoparticles made from amphiphiilic perfluoroalkyl ?-cyclodextrin derivatives: preparation, characterization and application to the transport of acyclovir. Int J Pharm 2009;375:155-62
67. Skiba M, Morvan C, Duchene D, Puisieux F. Evaluation of the gastrointestinal behaviour in the rat of amphiphilic β-cyclodextrin nanocapsules loaded with indomethacin. Int J Pharm 1995;126:275-9
68. Memisoglu-Bilensoy E, Hincal AA. Sterile injectable cyclodextrin nanoparticles: effects of gamma irradiation and autoclaving. Int J Pharm 2006:311:203-8
69. Uekama K, Horiuchi Y, Irie T, Hirayama F. O-carboxymethyl-O-ethyl- cyclomaltoheptaose as a delayed-release type drug carrier. Improvement of the oral availability of diltiazem. Carbohydr Res 1989;192:323-30
70. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev 1998;98:2045-76
71. Komiyama M, Takeshige Y, Sawada S. Complex formation of modified cyclodextrins with organic salts in organic solvents. Chem Lett 1984:1081-4
72. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery. An updated review. AAPS PharmSciTech 2005;6(2):E329-E357
73. Anand R, Nayyar S, Pitha J, Merril CR. Sulphated sugar alpha-cyclodextrin sulphate, a uniquely potent anti-HIV agent, also exhibits marked synergism with AZT, and lymphoproliferative activity. Antivir Chem Chemother 1990;1:41-6
74. M?ller BW, Brauns U. Hydroxypropyl-β-cyclodextrin derivatives: influence of average degree of substitution on complexing ability and surface activity. J Pharm Sci 1986;75:571-2
75. Yoshida A, Yamamoto M, Irie T, et al. Some pharmaceutical properties of 3-hydroxypropyl/ and 2,3-dihydroxypropyl β-cyclodextrins and their solubilizing and stabilizing ability. Chem Pharm Bull 1989;37:1059-63
76. Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery. Pharm Res 1997;14(5):556-67
77. Zia V, Rajewski R, Bornancini ER, et al. Effect of alkyl chain length and substitution degree on the complexation of sulfoalkyl ether β-cyclodextrins with steroids. Pharm Sci 1997:86:220-4
78. Ma DQ, Rajewski RA, Stella VJ. Thermal properties and processing of (sulfobutylether)-7M-β-cyclodextrin as a freeze-drying excipient in pharmaceutical formulations. STP Pharma Sci 1999;9(3):261-6
79. Friedman R. Cyclodextrin-containing polymers. In: Duchene D, editor, New trends in cyclodextrins and polymers. Paris, Editions de Santé; 1991. p. 157-78
80. Sebillé B. Cyclodextrin derivatives, In: Duchene D, editor, Cyclodextrins and their industrial uses. Paris: Editions de Santé; 1987. p. 351-93
81. Trichard L, Delgado-Charro MB, Guy RH, et al. Novel beads of alpha cyclodextrin and oil for topical delivery of a drug. Pharm Res 2008;25(2):435-40
82. Trichard L, Fattal E, Besnard M, Bochot A. Alpha cyclodextrin/oil beads as a new carrier for improving the oral bioavailability of lipophilic drugs. J Control Release 2007;122(1):47-53
83. Maestrelli F, Garcia-Fuentes M, Mura P, Alonso MJ. A new drug nanocarrier consisting of chitosan and hydoxypropylcyclodextrin. Eur J Pharm Biopharm 2006;69(2):79-86
84. Eguchi M, Da YZ, Ogawa Y, et al. Effects of conditions for preparing nanoparticles composed of aminoethylcarbamoyl-β-cyclodextrin and ethylene glycol diglycidyl ether on trap efficiency of a guest molecule. Int J Pharm 2006;311:215-22
85. Bellocq NC, Pun SH, Jensen GS, Davis ME. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 2003;14:1122-32
86. Hwang S, Bellocq N, Davis M. Effects of structure of beta-cyclodextrin- containing polymers on gene delivery. Bioconjug Chem 2001;12:280-90
87. Hede K. Blocking cancer with RNA interference moves toward the clinic. J Natl Cancer Inst 2005;97(4):626-8
88. Gao H, Wang YN, Fan YG, Ma JB. Conjugates of poly(DL-lactic acid) with ethylenediamino or diethylenetriamino bridged bis(β-cyclodextrin)s and their nanoparticles as protein delivery systems. J Control Release 2006;112:301-11
89. Gao H, Wang YN, Fen YG, Ma JB. Conjugation of poly(DL-lactide-co- glycolide) on amino cyclodextrins and their properties as protein delivery system. J Biomed Mater Res A 2007;80A:111-22
90. Wang H, Chen Y, Liu XY. Synthesis of oligo(ethylenediamino)- β-cyclodextrin modified gold nanoparticles as a DNA concentrator. Mol Pharm 2007;4(2):189-98
91. Park IK, van Recum HA, Jiang S, Pun SH. Supramolecular assembly of cyclodextrin-based nanoparticles on solid surfaces for gene delivery. Langmuir 2006;22:8478-84
92. Cavalli R, Peira E, Caputo O, Gasco MR. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrins. Int J Pharm 1999;182:59-69
93. Radwan MA. Preparation and in vivo evaluation of parenteral metoclopramide-loaded poly(alkylcyanoacrylate) nanospheres in rats. J Microencapsul 2001;18:467-77
94. Luppi B, Cerchiara T, Bigucci F, et al. Bovine serum albumin nanospheres carrying progesterone inclusion complexes. Drug Deliv 2005;12:281-7
95. Boudad H, Legrand P, Lebas G, et al. Combined hydroxypropyl-beta- cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm 2001;218:113-24
96. Salmaso S, Semenzato A, Calceti P, et al. Specific antitumor targetable β-cyclodextrin poly(ethyleneglycol)-folic acid bioconjugate. Bioconjug Chem 2004;15(5):997-1004
97. Salmaso S, Bersani S, Semenzato A, Caliceti P. New cyclodextrin bioconjugates for active tumor targeting. J Drug Target 2007;15(6):379-90